Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

CTCX

NASDAQ:CTCX

Carmell Therapeutics Corporation

Last Close

1.00

26/07 20:00

Market Cap

31.47M

Beta: 0.41

Volume Today

31.44K

Avg: 10.16K

PE Ratio

−2.98

PFCF: −9.08

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics